JP2016513723A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016513723A5 JP2016513723A5 JP2016502690A JP2016502690A JP2016513723A5 JP 2016513723 A5 JP2016513723 A5 JP 2016513723A5 JP 2016502690 A JP2016502690 A JP 2016502690A JP 2016502690 A JP2016502690 A JP 2016502690A JP 2016513723 A5 JP2016513723 A5 JP 2016513723A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- item
- formulated
- thiosemicarbazone
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 21
- -1 thiosemicarbazone compound Chemical class 0.000 claims description 7
- XMYKNCNAZKMVQN-NYYWCZLTSA-N [(e)-(3-aminopyridin-2-yl)methylideneamino]thiourea Chemical compound NC(=S)N\N=C\C1=NC=CC=C1N XMYKNCNAZKMVQN-NYYWCZLTSA-N 0.000 claims description 4
- 238000007918 intramuscular administration Methods 0.000 claims description 4
- 238000007912 intraperitoneal administration Methods 0.000 claims description 4
- 239000002502 liposome Substances 0.000 claims description 4
- 238000007920 subcutaneous administration Methods 0.000 claims description 4
- 230000000699 topical effect Effects 0.000 claims description 4
- 208000027104 Chemotherapy-Related Cognitive Impairment Diseases 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 229960005526 triapine Drugs 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims 2
- 230000001149 cognitive effect Effects 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 150000003584 thiosemicarbazones Chemical class 0.000 claims 1
- 238000000034 method Methods 0.000 description 13
- 229940102223 injectable solution Drugs 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000004530 micro-emulsion Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/803,482 | 2013-03-14 | ||
| US13/803,482 US20140271812A1 (en) | 2013-03-14 | 2013-03-14 | Treatment for chemotherapy-induced cognitive impairment |
| PCT/US2014/028039 WO2014152864A1 (en) | 2013-03-14 | 2014-03-14 | Treatment for chemotherapy-induced cognitive impairment |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018013721A Division JP2018062537A (ja) | 2013-03-14 | 2018-01-30 | 化学療法誘発認知障害の処置 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016513723A JP2016513723A (ja) | 2016-05-16 |
| JP2016513723A5 true JP2016513723A5 (enExample) | 2017-04-13 |
| JP6293258B2 JP6293258B2 (ja) | 2018-03-14 |
Family
ID=51528048
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016502690A Expired - Fee Related JP6293258B2 (ja) | 2013-03-14 | 2014-03-14 | 化学療法誘発認知障害の処置 |
| JP2018013721A Withdrawn JP2018062537A (ja) | 2013-03-14 | 2018-01-30 | 化学療法誘発認知障害の処置 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018013721A Withdrawn JP2018062537A (ja) | 2013-03-14 | 2018-01-30 | 化学療法誘発認知障害の処置 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20140271812A1 (enExample) |
| EP (1) | EP2968319B1 (enExample) |
| JP (2) | JP6293258B2 (enExample) |
| CA (1) | CA2905403A1 (enExample) |
| WO (1) | WO2014152864A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2984379C (en) | 2015-04-28 | 2024-06-11 | Newsouth Innovations Pty Limited | Targeting nad+ to treat chemotherapy and radiotherapy induced cognitive impairment, neuropathies, and inactivity |
| WO2019147839A1 (en) * | 2018-01-24 | 2019-08-01 | Sensei Biotherapeutics, Inc. | Methods and compositions for preserving neurogenesis |
| KR20230124625A (ko) * | 2020-12-24 | 2023-08-25 | 산텐 세이야꾸 가부시키가이샤 | 에피나스틴 또는 그의 염과 황계 항산화제를 함유하는경피 투여용 의약 조성물 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4447427A (en) | 1979-01-04 | 1984-05-08 | The United States Of America As Represented By The Secretary Of The Army | Method for treating bacterial infections with 2-acetyl- and 2-propionylpyridine thiosemicarbazones |
| US5180831A (en) * | 1990-08-10 | 1993-01-19 | Georgia Tech Research Corporation | Quaternary pyridinium compounds |
| US5281715A (en) | 1992-05-13 | 1994-01-25 | Yale University | 2-formylpyridine thiosemicarbazone compounds |
| US6114376A (en) * | 1997-04-30 | 2000-09-05 | Mcgill University | Methods for using macrocyclic lactone compounds as multidrug resistance reversing agents in tumor and other cells |
| US5869676A (en) | 1997-05-15 | 1999-02-09 | Vion Pharmaceuticals, Inc. | Process for the synthesis of ribonucleotide reductase inhibitors 3-AP and 3-AMP |
| US5767134A (en) | 1997-05-15 | 1998-06-16 | Vion Pharmaceuticals, Inc. | Prodrug forms of ribonucleotide reductase inhibitors 3-AP and 3-AMP |
| CA2525298A1 (en) | 2003-05-01 | 2004-11-18 | Panacea Pharmaceuticals, Inc. | Methods of treating ischemic related conditions |
| US20060194810A1 (en) | 2004-04-30 | 2006-08-31 | Bijan Almassian | Methods of treating ischemic related conditions |
| US20070243132A1 (en) * | 2005-12-22 | 2007-10-18 | Apollo Life Sciences Limited | Transdermal delivery of pharmaceutical agents |
| US20080039471A1 (en) * | 2006-08-14 | 2008-02-14 | Ghanbari Hossein A | Composition and method to inhibit tissue plasminogen activator (tPA) - potentiated neurotoxicity |
| US8034815B2 (en) * | 2007-01-11 | 2011-10-11 | Critical Outcome Technologies, Inc. | Compounds and method for treatment of cancer |
| WO2009139925A1 (en) * | 2008-05-16 | 2009-11-19 | Panacea Pharmaceuticals, Inc. | Methods for the treatment of brain edema |
| US20100120763A1 (en) * | 2008-11-07 | 2010-05-13 | Wyeth | Imidazo[5,1-c][1,2,4]benzotriazine derivatives as inhibitors of phosphodiesterases |
| AU2009326867B2 (en) * | 2008-12-12 | 2015-10-29 | The University Of Melbourne | Process for the preparation of asymmetrical bis(thiosemicarbazones) |
| US9700579B2 (en) * | 2011-04-27 | 2017-07-11 | Yale University | Drug therapy to inhibit chemotherapy-induced adverse effects and related pharmaceutical compositions, diagnostics, screening techniques and kits |
-
2013
- 2013-03-14 US US13/803,482 patent/US20140271812A1/en not_active Abandoned
-
2014
- 2014-03-14 JP JP2016502690A patent/JP6293258B2/ja not_active Expired - Fee Related
- 2014-03-14 CA CA2905403A patent/CA2905403A1/en not_active Abandoned
- 2014-03-14 EP EP14770876.2A patent/EP2968319B1/en active Active
- 2014-03-14 WO PCT/US2014/028039 patent/WO2014152864A1/en not_active Ceased
-
2018
- 2018-01-30 JP JP2018013721A patent/JP2018062537A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016518437A5 (enExample) | ||
| UA124347C2 (uk) | Циклічна динуклеотидна сполука | |
| MX384836B (es) | Agentes antivirales contra la hepatitis b | |
| PH12018550201A1 (en) | Hepatitis b antiviral agents | |
| JP2016503793A5 (enExample) | ||
| CL2021002747A1 (es) | Agentes antivirales para la hepatitis b (solicitud divisional no. 487-2020) | |
| UY37998A (es) | Agentes antivirales contra la hepatitis b | |
| NZ734019A (en) | Novel micro-dystrophins and related methods of use | |
| BR112015022197A8 (pt) | uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia | |
| JP2016510326A5 (enExample) | ||
| EP3954679A3 (en) | Amide compounds for the treatment of hiv infections | |
| JP2016517851A5 (enExample) | ||
| JP2018515557A5 (enExample) | ||
| JP2015110588A5 (enExample) | ||
| JP2019516735A5 (enExample) | ||
| JP2015051983A5 (enExample) | ||
| NI201800014A (es) | Inhibidor de la isocitrato deshidrogenasa mutada idh1 r132h | |
| JP2016503797A5 (enExample) | ||
| AR092993A1 (es) | Laquinimod para reducir el daño talamico en la esclerosis multiple | |
| JP2015521156A5 (enExample) | ||
| MD4760B1 (ro) | Compoziţii şi metode de tratament al infecţiilor provocate de viruşii hepatitei B şi hepatitei D | |
| RU2014117707A (ru) | Способ лечения пролиферативного заболевания | |
| RU2018101431A (ru) | Ингибиторы индоламин-2,3-диоксигеназы | |
| JP2018521056A5 (enExample) | ||
| JP2011046708A5 (enExample) |